Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463032 | 0.89 | PTK2 (0.34) | PTK2CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL3463729 | 0.82 | CHRNB2 (0.39) | HDAC4CHRNB2CHRNA4 | |
| SCHEMBL3463383 | 0.82 | ROCK1 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL3463109 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL3463289 | 0.80 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL3463251 | 0.78 | CHRNB2 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL3463460 | 0.77 | CHRNB2 (0.42) | HDAC4CHRNB2CHRNA4 | |
| SCHEMBL3464131 | 0.77 | CHRNB2 (0.46) | CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL3463104 | 0.76 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL3464372 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | claimed |
| US-7754708-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | claimed |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | BHATTI BALWINDER | 2008-10-02 | — | — | US | claimed |
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | claimed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754708-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | BHATTI BALWINDER | 2008-10-02 | — | — | US | disclosed |
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | disclosed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | MUSK, TNNC1, CHRNA5 | HDAC4 3174/4885PTK2 3132/4885CYP2A6 96/4885 |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | MUSK, TNNC1, CHRNA5 | HDAC4 3174/4885PTK2 3132/4885CYP2A6 96/4885 |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | OPRL1, OPRK1, ACHE | HDAC4 2090/4885PTK2 3259/4885CYP2A6 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.